Oncolytic Virus Therapy Market

Introduction
1. Market Definition
2. Market Segmentation
3. Product Overview
Assumptions and Acronyms
Research Methodology
1. Research Process
2. Primary Research
  1. Manufacturers
  2. End-Users
3. Secondary Research
4. Market Size Estimation
Executive Summary - Global Oncolytic Virus Therapy Market (2019-2028)
Analysis of Market Dynamics
1. Growth drivers
2. Opportunities
3. Market Trends
4. Restraints
Regulatory & Standards Landscape
1. Manufacturing Standards & Compliances
2. Environmental Compliances
Analysis on the Mechanism of Oncolytic Virus Therapy
Recent Developments in Oncolytic Virus Therapy Market
Pipeline Analysis
1. Clinical Trial Outlook
Epidemiology Analysis
Oncolytic Virus Platforms Under Evaluation
1. Adenovirus
2. Herpes Simplex Virus
3. Maraba Virus
4. Measles
5. Newcastle Disease Virus
6. Others
Impact of COVID-19 on the Oncolytic Virus Therapy Market
1. Impact of COVID-19 on the Overall Healthcare Sector
2. Impact on Demand
3. Impact on the Cancer Treatment
4. Impact on the Manufacturers
5. Impact on the Research & Development Activities
6. Impact on the Product Pipeline
7. Impact on the Key Market Players
8. Impact on the New Entrants in the Market
9. Impact on the Pricing
10. Market Impact Analysis in 2020 (quarter wise) w.r.t COVID-19 Pandemic (USD Million)
Analysis on the Oncolytic Virus Therapy
Analysis on the Oncolytic Virus Therapy Cost, USD
End-User Analysis
Competitive Structure (Both Marketed and Pipeline Drugs)
1. Market Share Analysis, 2020
2. Profiled Companies
  1. Amgen Inc.
  2. Shanghai Sunway Biotech Co., Ltd.
  3. Oncolys BioPharma Inc.
  4. TILT Biotherapeutics Ltd.
  5. Oncorus, Inc.
  6. Takara Bio Inc.
  7. Vyriad
  8. Transgene sa
  9. Lokon Pharma AB
  10. Pfizer Inc.
Oncolytic Virus Therapy Market Outlook
1. By Value (USD Million)
Oncolytic Virus Therapy Market Segmentation Analysis 2019-2028
1. By Therapy Type
  1. HSV-Based Oncolytic Virus Therapy, 2019-2028F (USD Million)
  2. Adenovirus-Based Oncolytic Virus Therapy, 2019-2028F (USD Million)
  3. Reovirus
  4. Poxviruses
  5. NDV (Newcastle Disease Virus)
  6. Others (Measles Virus; HVJ-E; SVV; Retrovirus; Parvovirus; Gamma-herpes Virus)
2. By Virus Type
  1. Oncolytic Wild Type Viruses, 2019-2028F (USD Million)
  2. Genetically Engineered Oncolytic Viruses, 2019-2028F (USD Million)
3. By Indication
  1. Head & Neck Cancer, 2019-2028F (USD Million)
  2. Lung Cancer, 2019-2028F (USD Million)
  3. Kidney Cancer, 2019-2028F (USD Million)
  4. Liver Cancer, 2019-2028F (USD Million)
  5. Pancreatic Cancer, 2019-2028F (USD Million)
  6. Breast Cancer, 2019-2028F (USD Million)
  7. Colorectal Cancer, 2019-2028F (USD Million)
  8. Sarcoma, 2019-2028F (USD Million)
    1. Bone Cancer, 2019-2028F (USD Million)
    2. Angiosarcoma, 2019-2028F (USD Million)
    3. Fibrosarcoma, 2019-2028F (USD Million)
    4. Leiomyosarcoma, 2019-2028F (USD Million)
    5. Others, 2019-2028F (USD Million)
  9. Melanoma, 2019-2028F (USD Million)
  10. Others, 2019-2028F (USD Million)
4. By Demography
  1. Pediatric, 2019-2028F (USD Million)
  2. Adults, 2019-2028F (USD Million)
5. By End-User
  1. Hospitals, 2019-2028F (USD Million)
  2. Hospitals, 2019-2028F (USD Million)
  3. Cancer Research Institutes, 2019-2028F (USD Million)
Oncolytic Virus Therapy Market, By Region, 2019-2028
1. North America, 2019-2028F (USD Million): U.S.
2. Europe, 2019-2028F (USD Million): Germany, U.K., France, Italy, Spain and Rest of Europe
3. Asia Pacific, 2019-2028F (USD Million): China, Japan, Australia and Rest of Asia-Pacific
4. Rest of World, 2019-2028F (USD Million)
Regional Oncolytic Virus Therapy Market Outlook (North America, Europe, Asia-Pacific and Rest of World)
1. Leading Companies in Oncolytic Virus Therapy Market
2. Assessment of macroeconomic factors
3. Analysis on the Development of Oncolytic Virus Therapies
Global & Regional Oncological Market Overview (2019-2028)

Preview Analysis

Request Insights

Despite Inflation & Recession News, Businesses Across the Globe Expected to Do Better in 2023

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

In The News

August 28, 2020: Lokon Pharma AB announced that it has partnered with Roche to evaluate the immunostimulatory armed gene therapy virus of Lokon, LOAd703, in combination with the programmed cell death ligand 1 (PD-L1)-blocking checkpoint inhibitor (CPI) of Roche, Tecentriq, in the patients suffering from metastatic colorectal cancer.

Global Oncolytic Virus Therapy Market Highlights Over 2019 - 2028

The global oncolytic virus therapy market is estimated to grow with a CAGR of 27.29% over the forecast period, i.e., 2021 – 2028. The growth of the market can primarily be attributed to the rising incidences of cancer and for the need to cure such chronic diseases. According to the statistics by the World Health Organization (WHO), globally, cancer is the leading cause of deaths and in the year 2020, it accounted for about 10 Million deaths. Out of the most common new cancer cases in the year 2020, breast and lung cancer held the highest share, registering 2.26 Million cases and 2.21 Million cases respectively. Cancer incidences have risen steadily across the world owing to the growing and aging population globally, and for the increasing exposure to cancer risk factors. The rising concern for such cases is driving the need for advanced cancer detection and treatment procedures, which is expected to contribute to the growth of the market during the forecast period. The global oncolytic virus therapy market garnered a revenue of USD 160.4 Million in the year 2019 and is further expected to touch USD 1062.7 Million by the end of 2028.

oncolytic virus therapy market Graph Moreover, the rising demand for targeted cancer therapies, backed by the rapid advancements in cancer research, and the surge in approval of immuno-oncology drugs by the medical fraternities, are also expected to accelerate the market growth in the coming years. Furthermore, rising healthcare expenditure, which according to the World Bank, as a share of GDP, grew from 9.417% in 2013 to 9.857% in 2018, is also one of the major factors anticipated to drive the market growth. CLICK TO DOWNLOAD SAMPLE REPORT

Current Health Expenditure Graph

Global Oncolytic Virus Therapy Market Regional Synopsis

Regionally, the global oncolytic virus therapy market is segmented into North America, Europe, Asia Pacific, and the Rest of World. Amongst the market in these regions, the market in North America is projected to hold the highest market share during the forecast period. In 2019, the market in the region garnered a revenue of USD 68.5 Million, and is further projected to reach USD 509.4 Million by the end of 2028. Rising awareness amongst individuals for different cancer treatments, increasing availability of advanced immune-oncology drugs in the region, along with the growing healthcare spending in countries such as the United States, are some of the major factors anticipated to drive the market growth in the region. According to the statistics by the American Cancer Society, in the United States, around 1.9 Million new cancer cases are expected to be diagnosed. Further, around 608570 deaths caused due to cancer is expected in the country in the same year.

The market in Europe, on the other hand, is expected to garner the second-largest market revenue of USD 295.5 Million by the end of 2028. Amongst the countries in the region, the market in the United Kingdom is projected to garner the largest market revenue of USD 83.1 Million by the end of 2028 by growing from a revenue of USD 10.8 Million in 2019.

Growth Drivers and Challenges Impacting the Growth of the Global Oncolytic Virus Therapy Market

Growth Drivers

Growing Cancer Cases Worldwide
Increasing Demand for Targeted Therapy
Rising Healthcare Expenditure Globally
Rapid Advancements in Healthcare Research

Challenges

Stringent Regulatory Standards
High Cost of Cancer Drug Development

Get more information on this report: Request Sample PDF

Global Oncolytic Virus Therapy Market Segmentation Synopsis

The global oncolytic virus therapy market is segmented by therapy type into HSV-based oncolytic virus therapy, adenovirus-based oncolytic virus therapy, reovirus, poxviruses, Newcastle disease virus (NDV), and others. Amongst these segments, the adenovirus-based oncolytic virus therapy segment held the highest market share of 30.2% in the year 2019 and is further projected to attain a significant market share by the end of 2028. On the basis of virus type, the market is segmented into oncolytic wild type viruses and genetically engineered oncolytic viruses, out of which, the genetically engineered oncolytic viruses segment is expected to hold the largest market share throughout the forecast period. Further, based on virus type, the market is segmented into head & neck cancer, lung cancer, kidney cancer, liver cancer, pancreatic cancer, breast cancer, colorectal cancer, sarcoma, melanoma, and others. Out of these, the colorectal cancer segment registered the second-highest market share of 11.1% in the year 2019. The segment is further expected to attain a significant market revenue by the end of 2028. On the basis of demography, the market is segmented into adults and pediatric, out of which, the adults segment is projected to gain the highest market share throughout the forecast period. The market is also segmented on the basis of end of end-user into hospitals, specialty clinics, and cancer research institutes, out of which, the hospitals segment held the highest market share of 46.60% in the year 2019.

Key Companies Dominating the Market

Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global oncolytic virus therapy market that are included in our report are Amgen Inc., Shanghai Sunway Biotech Co., Ltd., Oncolys BioPharma Inc., TILT Biotherapeutics Ltd., Oncorus, Inc., Takara Bio Inc., Vyriad, Transgene sa, Lokon Pharma AB, Pfizer Inc., and others.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the oncolytic virus therapy market?

Ans: The increasing incidences of cancer worldwide, along with the growing demand for targeted therapy are some of the major factors anticipated to drive the market growth.

2) What would be the CAGR of oncolytic virus therapy market over the forecast period?

Ans: The market is anticipated to attain a CAGR of 27.29% over the forecast period, i.e., 2021-2028.

3) What are the challenges affecting the oncolytic virus therapy market growth?

Ans: The high cost of cancer drug development is one of the major factors estimated to hamper the market growth.

4) Which region will provide more business opportunities for growth of oncolytic virus therapy market in future?

Ans: The market in Europe is expected to garner the second-largest market revenue of USD 295.5 Million by the end of 2028 and provide more business opportunities in the future.

5) Who are the major players dominating the oncolytic virus therapy market?

Ans: The major players in the market are Amgen Inc., Shanghai Sunway Biotech Co., Ltd., Oncolys BioPharma Inc., TILT Biotherapeutics Ltd., Oncorus, Inc., and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the oncolytic virotherapy market?

Ans: The market is segmented by therapy type, virus type, indication, demography, end-user, and by region.

8) Which segment captures the largest market size in therapy type segment in the oncolytic virus therapy market?

Ans: The adenovirus-based oncolytic virus therapy segment held the highest market share of 30.2% in 2019 and is expected to display significant growth opportunities throughout the forecast period.